Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102189 · ClinicalTrials.gov registry record · Phase 3
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
NCT04102189 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 201 participants.
The verdict
NCT04102189, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
Study Summary
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - which treatment is decided by chance. The teenagers will take 1 injection every week, on the same day of the week for about 15 months. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The teenagers will have 17 clinic visits, will have blood samples taken and will have to complete questionnaires and keep a diary. All this will be explained before study start.
Interventions
- OTHER Placebo
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04102189
The ClinicalTrials.gov registry entry for NCT04102189 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04102189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04102189 about?
NCT04102189 is a clinical study titled "A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity". This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks ...
What is the current status of trial NCT04102189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2019-10-07. Estimated completion is 2022-03-28.
What interventions are being tested in trial NCT04102189?
The interventions under investigation include: Placebo (OTHER), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT04102189?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.